Enveric Biosciences Inc vs VNET Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.35 (market cap $5.32M), while VNET Group Inc trades at $7.87 (market cap $2.25B). The key difference: VNET Group Inc is far larger — about 422.9× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.
| ENVB | VNET | |
|---|---|---|
Market Cap | $5.32M | $2.25B |
Sector | Health | Technology |
52-Week High | $17.40 | $14.03 |
52-Week Low | $1.28 | $7.34 |
Enterprise Value | $408.82K | $5.38B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNET Group trades at $7.86, up 1.42% with bearish technical signals but strong analyst support. The company reported Q1 2026 revenue growth driven by AI demand, though net losses widened to -$1.20 per share. Recent strategic investments and leadership changes signal transformation, while a class action settlement adds legal overhang. The stock shows mixed fundamentals with negative profitability metrics but positive cash flow from operations.
VNET presents a high-risk opportunity with Wall Street optimism (62.5% buy ratings) pointing to 54% upside potential. Key risks include persistent losses, competitive pressures, and China market exposure. The AI-driven data center expansion offers growth potential, but investors need confidence in the path to profitability amid ongoing operational challenges.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →